Annual Safety report the COVID STEROID 2 trial

EudraCT number	**2020-003363-25**
Clinical Trial Title	**Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial**
Sponsor	**Anders Perner, Professor, Senior staff specialist**
Designated reporter	**Ditto**
Medicines Agency journal number	**2020-07-16**
Ethics Committees case number	**H-20051056**
Date of initial authorization	**2020-08-21**

Period of reporting: August 27, 2020 to June 19, 2021
Initiation of trial: August 27, 2020
Last patient included: May 20, 2021
Last patient's safety follow-up (28 days): June 18 2021

SAR/SAE in the period of reporting:
Number of SARs/SAEs: 328
Number of patients with 1 or more SAR/SAEs: 225
1000 patients enrolled; 982 patients analyzed.

SUSAR in the period of reporting:
Number of SUSARs: 0
1000 patients enrolled; 982 patients analyzed.

Conclusions on the observed SAR/SAE/SUSAR:
The number of SARs/SAEs are as expected in this population of severely ill patients and in any case similar between the 2 intervention groups as presented in the table below (copied from the primary trial report, which has been accepted for publication in a peer-reviews medical journal).

eTable 10. All Serious Adverse Reactions and Serious Adverse Events[a]

	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)
SARs registered in addition to those in the SAR-outcome, no. (%)[b]		
Sepsis	2 (0.4%)	5 (1.0%)
Bacteraemia	4 (0.8%)	1 (0.2%)
Pneumonia	6 (1.2%)	7 (1.4%)
C. difficile	0 (0.0%)	1 (0.2%)
Other	3 (0.6%)	3 (0.6%)
Total[c]	14 (2.8%)	17 (3.5%)
SAEs, no. (%)[d]		
Thromboembolic events	4 (0.8%)	10 (2.1%)
Bleeding	7 (1.4%)	7 (1.4%)
Acute kidney injury reported or new use of RRT	41 (8.2%)	52 (10.7%)
Pulmonary complications, including pneumothorax	3 (0.6%)	3 (0.6%)
Circulatory failure, including cardiac arrest	9 (1.8%)	9 (1.9%)
Other	7 (1.4%)	3 (0.6%)
Total[e]	70 (14.1%)	85 (17.5%)
Patients with one or more SARs or SAEs, no. (%)[f]	102 (20.5%)	123 (25.4%)

Abbreviations: mg, milligrams; RRT, renal replacement therapy; SAE, serious adverse event; SAR, serious adverse reaction.

[a] SAE and any SAR (both those included in the SAR-outcome (i.e. new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding, or anaphylactic reaction to intravenous dexamethasone), the use of RRT-outcome (excluding those using RRT at baseline) and those reported directly to Sponsor or his delegate by e-mail or using a standardized report form).

[b] Other registered SARs, i.e. adverse reactions registered in the Summary Product Characteristic for dexamethasone considered serious and not registered in the secondary SAR outcome.

[c] Total number of patients with at least one SAR not included in the secondary SAR outcome.

[d] Any SAE not considered a SAR.

[e] Total number of patients with at least one SAE.

[f] Including the reactions reported in the secondary SAR outcome.

Benefit-risk evaluation:

Based on the above reported, the risk and benefits for the patients are considered unchanged. In any case, the trial recruitment has stopped as the planned sample size was reseach.

Implication for the clinical trial population:

Change in / amendment to protocol	☐ **yes**	**X no**
Change in study procedures	☐ **yes**	**X no**
Change in patient information	☐ **yes**	**X no**
Change in informed consent form	☐ **yes**	**X no**

Date: October 8, 2021

Signature: _____